# Study Of Sunitinib Malate Versus Sorafenib In Patients With Inoperable Liver Cancer

> **NCT00699374** · PHASE3 · TERMINATED · sponsor: **Pfizer** · enrollment: 1075 (actual)

## Conditions studied

- Carcinoma, Hepatocellular

## Interventions

- **DRUG:** sunitinib malate
- **DRUG:** sorafenib

## Key facts

- **NCT ID:** NCT00699374
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-07
- **Primary completion:** 2011-12
- **Final completion:** 2011-12
- **Target enrollment:** 1075 (ACTUAL)
- **Why stopped:** See termination reason in detailed description.
- **Last updated:** 2013-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00699374

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00699374, "Study Of Sunitinib Malate Versus Sorafenib In Patients With Inoperable Liver Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00699374. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*